Therapeutic strategies targeting the interaction between estrogen and the ER or their downstream signaling have been demonstrated effective in improving the prognosis of HR+ breast cancer, and development of new drugs is always a hot topic for endocrine therapy worldwide [48–50]. The gene discussed is ESR1; the disease is breast carcinoma.